Latest Conference Articles

February 28th 2015, 3:03pm

PER® Miami Breast Cancer Conference

Heterogeneity, which can result in treatment resistance, is commonly underestimated and misunderstood, representing an important area of future research.

February 28th 2015, 2:40pm

PER® Miami Breast Cancer Conference

In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.

February 28th 2015, 11:55am

PER® Miami Breast Cancer Conference

George W. Sledge, Jr., MD, professor of medicine, Stanford University School of Medicine, explains how tumor heterogeneity impacts patient care and research.

February 28th 2015, 11:49am

Genitourinary Cancers Symposium (ASCO GU)

Ramucirumab added to docetaxel significantly improved PFS compared with docetaxel monotherapy as second-line treatment in a phase II study of patients with metastatic transitional cell carcinoma.

February 28th 2015, 9:22am

PER® Miami Breast Cancer Conference

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

February 28th 2015, 7:45am

Genitourinary Cancers Symposium (ASCO GU)

In patients evaluable for treatment response, the ORR with the combination was 50%, with 11% having a CR.

February 27th 2015, 5:45pm

Genitourinary Cancers Symposium (ASCO GU)

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

February 27th 2015, 3:48pm

PER® Miami Breast Cancer Conference

Moving early to diagnose and treat lymphedema after breast cancer treatment can reverse this side effect or prevent it from becoming more severe.

February 27th 2015, 2:50pm

Genitourinary Cancers Symposium (ASCO GU)

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

February 27th 2015, 1:20pm

PER® Miami Breast Cancer Conference

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

February 27th 2015, 1:02pm

Genitourinary Cancers Symposium (ASCO GU)

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses the performance of the cell cycle progression (CCP) assay for prostate cancer.

February 27th 2015, 12:03pm

PER® Miami Breast Cancer Conference

While not appropriate for all patients with ER-positive breast cancer, neoadjuvant endocrine therapy could play an important role in select groups of women with comorbidities or those with ER-rich/luminal A disease.

February 27th 2015, 11:56am

Genitourinary Cancers Symposium (ASCO GU)

Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

February 27th 2015, 11:08am

Genitourinary Cancers Symposium (ASCO GU)

The beneficial effect of abiraterone acetate on overall survival in men with progressive metastatic CRPC in the COU-AA-302 study becomes even more pronounced after adjustment for crossover from placebo to active treatment.

February 27th 2015, 10:11am

PER® Miami Breast Cancer Conference

The FDA's recent approval of the first PARP inhibitor suggests that this new class of targeted therapy has great potential to help not only patients with ovarian cancer for whom the agent is indicated but also individuals with breast cancer.

February 27th 2015, 9:44am

Genitourinary Cancers Symposium (ASCO GU)

Androgen deprivation therapy with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, an updated analysis of a randomized trial showed.

February 27th 2015, 7:57am

Genitourinary Cancers Symposium (ASCO GU)

A phase I study conducted at the NIH, combining a fixed dose of PROSTVAC with escalating doses of the checkpoint inhibitor ipilimumab, produced encouraging survival results in mCRPC.

February 26th 2015, 1:46pm

PER® Miami Breast Cancer Conference

Debu Tripathy, MD, professor of medicine, chair, department of breast medical oncology, The University of Texas MD Anderson Cancer Center, discusses the possibility of one day being able to cure metastatic breast cancer.

February 26th 2015, 1:10pm

PER® Miami Breast Cancer Conference

Deanna J. Attai, MD, breast surgeon, assistant clinical professor of surgery, David Geffen School of Medicine, University of California, Los Angeles, explains how social media can help physicians.

February 26th 2015, 11:51am

Genitourinary Cancers Symposium (ASCO GU)

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses a study that looked at the impact of body mass index (BMI) on outcomes of patients with metastatic renal cell carcinoma (mRCC).